PharmaPoint: Prostate Cancer - United Kingdom Drug Forecast and Market Analysis to 2022


#163759

164pages

GlobalData

$ 4995

In Stock

PharmaPoint: Prostate Cancer - United Kingdom Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, PharmaPoint: Prostate Cancer - United Kingdom Drug Forecast and Market Analysis to 2022. The recent approvals of second-line metastatic castration-resistant prostate cancer (mCRPC) therapies like J&J’s Zytiga (abiraterone acetate) and Medivation/Astellas’ Xtandi (enzalutamide) will drive strong market growth over the next decade. 

These safe and orally administered treatments will provide safety and convenience benefits over the current standard of care, chemotherapy with docetaxel, while prolonging the overall survival of patients with mCRPC. 

The December 12, 2012 FDA approval of Zytiga for the added indication of chemotherapy-naïve mCRPC marks the onset of a new treatment paradigm for the disease, in which chemotherapy is relegated to second-line therapy and beyond. For patients with earlier-stage prostate cancer, androgen deprivation therapy with LHRH agonists and first-generation antiandrogens remains the standard of care for suppressing testosterone levels and temporarily controlling the disease.

Routine PSA screening is used to diagnose prostate cancer in the UK, although its uptake is not as widespread as in the US. DREs are also frequently used to search for abnormalities in the prostate (EAU, 2012). Multiple TRUS-guided core biopsies are used in order to confirm a diagnosis of prostate cancer in response to symptoms or high PSA levels. 

To identify metastases, physicians use bone scans or CT scans. According to GlobalData’s primary research, UK urologists and medical oncologists report that most of their patients were diagnosed and/or monitored using PSA screening. The majority of prescribing physicians do not anticipate any changes in screening patterns in response to the USPSTF recommendation against routine screening. Primary research indicates that while PSA screening is used to some extent, the UK is unlikely to institute a national screening program. Physicians feel that it is more appropriate to prevent overtreatment, and wait until the prostate cancer manifests with symptoms before treatment is initiated.

Scope
  • Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in the UK including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in the UK from 2012 to 2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting the UK Prostate cancer market.
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Prostate cancer
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Prostate cancer drug performance in the UK
  • Obtain sales forecast from 2012-2022 in The UK